Larimar Therapeutics Reports 2024 Financial Results and Development Progress
PremiumCompany AnnouncementsLarimar Therapeutics Reports 2024 Financial Results and Development Progress
13d ago
Promising Prospects for Larimar Therapeutics: Buy Rating Affirmed Amid FDA Support and Strong Financial Position
Premium
Ratings
Promising Prospects for Larimar Therapeutics: Buy Rating Affirmed Amid FDA Support and Strong Financial Position
13d ago
Larimar Therapeutics reports Q4 EPS (45c), consensus (32c)
Premium
The Fly
Larimar Therapeutics reports Q4 EPS (45c), consensus (32c)
13d ago
Truist sees ‘significant upside’ for Larimar Therapeutics, starts with a Buy
PremiumThe FlyTruist sees ‘significant upside’ for Larimar Therapeutics, starts with a Buy
2M ago
Larimar Therapeutics initiated with a Buy at Truist
Premium
The Fly
Larimar Therapeutics initiated with a Buy at Truist
2M ago
Larimar Therapeutics Aligns Executive Incentives with Milestones
Premium
Company Announcements
Larimar Therapeutics Aligns Executive Incentives with Milestones
2M ago
Larimar Therapeutics announces initial data from OLE study of nomlabofusp
PremiumThe FlyLarimar Therapeutics announces initial data from OLE study of nomlabofusp
4M ago
Larimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofusp
Premium
The Fly
Larimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofusp
5M ago
Citi opens ‘positive catalyst watch’ on Larimar Therapeutics into data
Premium
The Fly
Citi opens ‘positive catalyst watch’ on Larimar Therapeutics into data
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100